In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:

• Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
• The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
• Deal structures and the BD side of ADCs, and their extended revenue generation potential
• Where the field is headed, in terms of clinical, BD and commercial standpoints

Read and connect with our authors:  The Transactional Landscape Of ADCs: A Payday for Payloads